湿性年龄相关性黄斑变性患者玻璃体内注射抗血管内皮生长因子药物后的动脉硬化改变
Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration.
作者信息
Shiba Tomoaki, Takahashi Mao, Yoshida Izumi, Taniguchi Hikari, Matsumoto Tadashi, Hori Yuichi
机构信息
Department of Ophthalmology, School of Medicine, Toho University, Tokyo, Japan.
出版信息
Ophthalmologica. 2016;235(4):225-32. doi: 10.1159/000445388. Epub 2016 Apr 16.
PURPOSE
The aim of this study was to determine whether multiple intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs for age-related macular degeneration (AMD) exacerbate systemic arteriosclerosis, using the cardio-ankle vascular index (CAVI) and intima-media thickness (IMT).
METHODS
We analyzed the data of 45 AMD patients who received intravitreal injections of anti-VEGF drugs (ranibizumab and/or aflibercept) and underwent systemic evaluations at baseline and after treatment. Reevaluation was conducted at ≥12 months from the initial treatment.
RESULTS
The total number of intravitreal injections of overall anti-VEGF drugs was significantly correlated with x0394;serum cystatin C. The cumulative number of aflibercept injections was identified as an independent protective factor for x0394;CAVI. An increase in the cumulative number of intravitreal injections of overall anti-VEGF drugs was identified as a protective factor for x0394;mean IMT.
CONCLUSION
Repeated intravitreal injections of an anti-VEGF drug for AMD may lead to morphological and functional changes in large arteries.
目的
本研究旨在使用心踝血管指数（CAVI）和内膜中层厚度（IMT），确定多次玻璃体内注射抗血管内皮生长因子（VEGF）药物治疗年龄相关性黄斑变性（AMD）是否会加剧全身动脉硬化。
方法
我们分析了45例接受玻璃体内注射抗VEGF药物（雷珠单抗和/或阿柏西普）并在基线和治疗后进行全身评估的AMD患者的数据。在初始治疗后≥12个月进行重新评估。
结果
抗VEGF药物的玻璃体内注射总数与血清胱抑素C显著相关。阿柏西普注射的累积次数被确定为CAVI变化的独立保护因素。抗VEGF药物玻璃体内注射累积次数的增加被确定为平均IMT变化的保护因素。
结论
反复玻璃体内注射抗VEGF药物治疗AMD可能会导致大动脉的形态和功能变化。
Zotero 插件